Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444117 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL29822698 | 1.00 | ALDH1A1 (0.41) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| Bromide SCHEMBL1033291 | 0.96 | ALDH1A1 (0.39) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL1033292 | 0.93 | ALDH1A1 (0.37) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL2523285 | 0.89 | TDP1 (0.34) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL29513054 | 0.86 | MAPT (0.50) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL17606910 | 0.86 | MAPT (0.50) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL1768181 | 0.84 | MAPT (0.49) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| SCHEMBL1622430 | 0.84 | TDP1 (0.46) | ALDH1A1MAPTTDP1L3MBTL1NSD2 | |
| Bromide SCHEMBL7609603 | 0.82 | TDP1 (0.44) | ALDH1A1MAPTTDP1L3MBTL1NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 653 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427468-B2 | PREPARATION OF A METAL COMPLEX | JOHNSON MATTHEY PLC (GB) | 2025-06-04 | — | — | EP | claimed |
| EP-4267591-A2 | ORGANOMETALLIC COMPOUNDS | Umicore AG & Co. KG (DE) | 2023-11-01 | — | — | EP | claimed |
| WO-2022136049-A2 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2022-06-30 | — | — | WO | claimed |
| WO-2022103990-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PHOSFISH LLC (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220144883-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PHOSFISH LLC | 2022-05-12 | — | — | US | claimed |
| EP-2427468-B1 | PREPARATION OF A METAL COMPLEX | JOHNSON MATTHEY PLC (GB) | 2017-06-14 | — | — | EP | claimed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | claimed |
| WO-2009051417-A2 | PHENANTHRENE LACTAM DERIVATIVES HAVING ANTICANCER ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-04-23 | — | — | WO | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005123682-A1 | METHOD FOR THE PRODUCTION OF 5-ARYL NICOTINALDEHYDES | MERCK PATENT GMBH (DE) | 2005-12-29 | — | — | WO | claimed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | claimed |
| US-12606550-B2 | Methods for synthesis of CHK1 inhibitors | CRT PIONEER FUND LP (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-3927685-B1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD (IN) | 2025-10-08 | — | — | EP | disclosed |
| US-20020016509-A1 | Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds | YALE UNIVERSITY | 2002-02-07 | — | — | US | disclosed |
| US-6057456-A | CATALYTIC REACTION USING BASE AND METAL CATALYST FOR REACTION | YALE UNIVERSITY (US) | 2000-05-02 | — | — | US | disclosed |
| US-5977361-A | Transition metal-catalyzed process for preparing N-aryl compounds | YALE UNIVERSITY (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144883-A1 | METHODS OF MODIFYING PHOSPHORYLATED OR SULFATED TYROSINE RESIDUES OF POLYPEPTIDES | PTMS, ACP1, SRMS | ALDH1A1 4739/4885MAPT 2781/4885TDP1 1062/4885 |
| US-12606550-B2 | Methods for synthesis of CHK1 inhibitors | CHEK1, CHEK2, RAD1 | ALDH1A1 3198/4885MAPT 816/4885TDP1 131/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | ALDH1A1 463/4885MAPT 4729/4885TDP1 3610/4885 |
| US-20020016509-A1 | Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds | COASY, CMA1, ATIC | ALDH1A1 193/4885MAPT 1475/4885TDP1 3430/4885 |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, BRCA1 | ALDH1A1 826/4885MAPT 4558/4885TDP1 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.